Central Nervous System Leukemia [electronic resource] : Prevention and Treatment /

Central Nervous System Leukemia [electronic resource] : Prevention and Treatment /

Show other versions (1)

In the past 10 to IS years there has been dramatic improvement in the survival of children with acute lymphoblastic leukemia. At the present time, over 50% of children with this disease will be alive and free of their disease at least 5 years from the time of their initial diagnosis. Although a number of factors have contributed to this improvement, perhaps none has been as important as the institution of central nervous system preventive therapy (eNS prophylaxis). However, despite the efficacy of eNS prophylaxis, the prevention and treatment of central nervous system leukemia continues to pose a formidable clinical challenge to the pediatric oncologist. Although successful in most cases, eNS preventive therapy remains ineffective for a small but significant subset of patients at high risk for developing eNS disease. Moreover, it has become increasingly evident that some methods of eNS preventive therapy are associated with long-term, adverse eNS sequelae. Thus, considerable controversy exists regarding the optimal method of eNS prophylaxis. Treatment of the patient who develops overt meningeal leukemia has not been as successful and continues to pose a major clinical challenge. Despite the ability of intrathecal chemotherapy and/or radiation therapy to induce eNS remission, most patients suffer subsequent relapse and ultimate survival is usually signifi­ cantly compromised. It is evident that newer approaches to treatment for this patient group must be identified before major improvement for this patient group is likely to occur.

Saved in:
Bibliographic Details
Main Authors: Mastrangelo, Renato. editor., Poplack, David G. editor., Riccardi, Riccardo. editor., SpringerLink (Online service)
Format: Texto biblioteca
Language:eng
Published: Dordrecht : Springer Netherlands, 1983
Subjects:Medicine., Oncology., Medicine & Public Health.,
Online Access:http://dx.doi.org/10.1007/978-94-009-6708-3
Tags: Add Tag
No Tags, Be the first to tag this record!
id KOHA-OAI-TEST:184474
record_format koha
institution COLPOS
collection Koha
country México
countrycode MX
component Bibliográfico
access En linea
En linea
databasecode cat-colpos
tag biblioteca
region America del Norte
libraryname Departamento de documentación y biblioteca de COLPOS
language eng
topic Medicine.
Oncology.
Medicine & Public Health.
Oncology.
Medicine.
Oncology.
Medicine & Public Health.
Oncology.
spellingShingle Medicine.
Oncology.
Medicine & Public Health.
Oncology.
Medicine.
Oncology.
Medicine & Public Health.
Oncology.
Mastrangelo, Renato. editor.
Poplack, David G. editor.
Riccardi, Riccardo. editor.
SpringerLink (Online service)
Central Nervous System Leukemia [electronic resource] : Prevention and Treatment /
description In the past 10 to IS years there has been dramatic improvement in the survival of children with acute lymphoblastic leukemia. At the present time, over 50% of children with this disease will be alive and free of their disease at least 5 years from the time of their initial diagnosis. Although a number of factors have contributed to this improvement, perhaps none has been as important as the institution of central nervous system preventive therapy (eNS prophylaxis). However, despite the efficacy of eNS prophylaxis, the prevention and treatment of central nervous system leukemia continues to pose a formidable clinical challenge to the pediatric oncologist. Although successful in most cases, eNS preventive therapy remains ineffective for a small but significant subset of patients at high risk for developing eNS disease. Moreover, it has become increasingly evident that some methods of eNS preventive therapy are associated with long-term, adverse eNS sequelae. Thus, considerable controversy exists regarding the optimal method of eNS prophylaxis. Treatment of the patient who develops overt meningeal leukemia has not been as successful and continues to pose a major clinical challenge. Despite the ability of intrathecal chemotherapy and/or radiation therapy to induce eNS remission, most patients suffer subsequent relapse and ultimate survival is usually signifi­ cantly compromised. It is evident that newer approaches to treatment for this patient group must be identified before major improvement for this patient group is likely to occur.
format Texto
topic_facet Medicine.
Oncology.
Medicine & Public Health.
Oncology.
author Mastrangelo, Renato. editor.
Poplack, David G. editor.
Riccardi, Riccardo. editor.
SpringerLink (Online service)
author_facet Mastrangelo, Renato. editor.
Poplack, David G. editor.
Riccardi, Riccardo. editor.
SpringerLink (Online service)
author_sort Mastrangelo, Renato. editor.
title Central Nervous System Leukemia [electronic resource] : Prevention and Treatment /
title_short Central Nervous System Leukemia [electronic resource] : Prevention and Treatment /
title_full Central Nervous System Leukemia [electronic resource] : Prevention and Treatment /
title_fullStr Central Nervous System Leukemia [electronic resource] : Prevention and Treatment /
title_full_unstemmed Central Nervous System Leukemia [electronic resource] : Prevention and Treatment /
title_sort central nervous system leukemia [electronic resource] : prevention and treatment /
publisher Dordrecht : Springer Netherlands,
publishDate 1983
url http://dx.doi.org/10.1007/978-94-009-6708-3
work_keys_str_mv AT mastrangelorenatoeditor centralnervoussystemleukemiaelectronicresourcepreventionandtreatment
AT poplackdavidgeditor centralnervoussystemleukemiaelectronicresourcepreventionandtreatment
AT riccardiriccardoeditor centralnervoussystemleukemiaelectronicresourcepreventionandtreatment
AT springerlinkonlineservice centralnervoussystemleukemiaelectronicresourcepreventionandtreatment
_version_ 1756265239856283648
spelling KOHA-OAI-TEST:1844742018-07-30T23:06:15ZCentral Nervous System Leukemia [electronic resource] : Prevention and Treatment / Mastrangelo, Renato. editor. Poplack, David G. editor. Riccardi, Riccardo. editor. SpringerLink (Online service) textDordrecht : Springer Netherlands,1983.engIn the past 10 to IS years there has been dramatic improvement in the survival of children with acute lymphoblastic leukemia. At the present time, over 50% of children with this disease will be alive and free of their disease at least 5 years from the time of their initial diagnosis. Although a number of factors have contributed to this improvement, perhaps none has been as important as the institution of central nervous system preventive therapy (eNS prophylaxis). However, despite the efficacy of eNS prophylaxis, the prevention and treatment of central nervous system leukemia continues to pose a formidable clinical challenge to the pediatric oncologist. Although successful in most cases, eNS preventive therapy remains ineffective for a small but significant subset of patients at high risk for developing eNS disease. Moreover, it has become increasingly evident that some methods of eNS preventive therapy are associated with long-term, adverse eNS sequelae. Thus, considerable controversy exists regarding the optimal method of eNS prophylaxis. Treatment of the patient who develops overt meningeal leukemia has not been as successful and continues to pose a major clinical challenge. Despite the ability of intrathecal chemotherapy and/or radiation therapy to induce eNS remission, most patients suffer subsequent relapse and ultimate survival is usually signifi­ cantly compromised. It is evident that newer approaches to treatment for this patient group must be identified before major improvement for this patient group is likely to occur.1. The Pathology of Central Nervous System Leukemia -- 2. Radiation Therapy Methods for Central Nervous System ‘Prophylaxis’ in the Management of Childhood Leukemias -- 3. Central Nervous System Prophylaxis for Therapy of Acute Lymphocytic Leukemia -- 4. Reduction in Central Nervous System Leukemia with a Pharmaco-kinetically derived Intrathecal-Methotrexate Dosage Regimen -- 5. Central Nervous System Prophylaxis with Intermittent Intrathecal Methotrexate and Fractional Radiation in Childhood Acute Lymphoblastic Leukemia -- 6. Intermittent Intrathecal Methotrexate and Fractional Radiation plus Chemotherapy in Childhood Lymphoblastic Leukemia -- 7. Prophylaxis of Central Nervous System Leukaemia: British Experience, 1970–80 -- 8. The Norwegian Methotrexate Study in Childhood Acute Lymphocytic Leukemia -- 9. Therapy Related Central Nervous System Diseases in Children with Acute Lymphocytic Leukemia -- 10. Neurotoxic Complications of CNS Prophylaxis in Childhood Leukaemia -- 11. Evaluation of Adverse Sequelae of Central Nervous System Prophylaxis in Acute Lymphoblastic Leukemia -- 12. Adverse Sequelae of Central Nervous System Prophylaxis in Acute Lymphoblastic Leukemia -- 13. Treatment of Overt CNS Leukaemia -- 14. Radiation Therapy Methods for the Treatment of Central Nervous System Leukemia -- 15. Treatment of Meningeal Leukemia: Investigation of New Approaches with Conventional Agents.In the past 10 to IS years there has been dramatic improvement in the survival of children with acute lymphoblastic leukemia. At the present time, over 50% of children with this disease will be alive and free of their disease at least 5 years from the time of their initial diagnosis. Although a number of factors have contributed to this improvement, perhaps none has been as important as the institution of central nervous system preventive therapy (eNS prophylaxis). However, despite the efficacy of eNS prophylaxis, the prevention and treatment of central nervous system leukemia continues to pose a formidable clinical challenge to the pediatric oncologist. Although successful in most cases, eNS preventive therapy remains ineffective for a small but significant subset of patients at high risk for developing eNS disease. Moreover, it has become increasingly evident that some methods of eNS preventive therapy are associated with long-term, adverse eNS sequelae. Thus, considerable controversy exists regarding the optimal method of eNS prophylaxis. Treatment of the patient who develops overt meningeal leukemia has not been as successful and continues to pose a major clinical challenge. Despite the ability of intrathecal chemotherapy and/or radiation therapy to induce eNS remission, most patients suffer subsequent relapse and ultimate survival is usually signifi­ cantly compromised. It is evident that newer approaches to treatment for this patient group must be identified before major improvement for this patient group is likely to occur.Medicine.Oncology.Medicine & Public Health.Oncology.Springer eBookshttp://dx.doi.org/10.1007/978-94-009-6708-3URN:ISBN:9789400967083

Similar Items